| abstract |
Disclosed is a monoclonal antibody having an activity of neutralizing HB-EGF. Preferably, the monoclonal antibody is an antibody incapable of binding to an HB-EGF protein located on the surface of an HB-EGF-expressing cell. Further disclosed are: a cancer therapeutic agent and a cell proliferation inhibitor, each of which comprises the monoclonal antibody as an active ingredient; and a method for treating cancer, which comprises administering the monoclonal antibody. The types of cancer which can be treated by the cancer therapeutic agent include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, bladder cancer and brain tumor. |